What is Retatrutide?
Retatrutide (LY3437943) is a next-generation triple-agonist research peptide engineered to bind three incretin and glucose-regulating receptors simultaneously — GIP, GLP-1, and glucagon. By recruiting all three pathways at once, Retatrutide is one of the most pharmacologically distinct compounds currently being investigated in metabolic-pathway research.
Current investigational literature highlights Retatrutide's potency in pre-clinical and early clinical weight-management and metabolic studies, where the addition of glucagon-receptor activity is hypothesized to compound the energy-expenditure effects already established for GIP/GLP-1 dual-agonism.
How it's studied — mechanism
Retatrutide functions as a balanced agonist across three receptor populations:
- GIP receptor — modulation of incretin signaling and insulin secretion
- GLP-1 receptor — appetite regulation, satiety, gastric-emptying delay
- Glucagon receptor — hypothesized to drive additional energy expenditure and hepatic lipid mobilization
The combined-receptor profile differentiates Retatrutide from earlier mono- (GLP-1) and dual-agonist (GIP/GLP-1) research peptides.
Amino acid sequence
Modified 39-aa triple-agonist (see Coskun et al., 2022)Published research
The following primary sources are provided to support qualified-researcher review. Inclusion is for reference only and does not constitute medical advice or therapeutic claim.